Themis pushes into PhII with Chikungunya vax candidate

mosquito

Even though many people around the world currently have a laser focus on Zika, development projects for vaccines against other mosquito-borne viruses remain important. This week, Austrian biotech Themis Bioscience said it’s starting a Phase II for its Chikungunya virus vaccine, what it calls “the most advanced” candidate of its kind.

Themis will test its Chikungunya vaccine in a dose confirmation study with 320 volunteers who will receive a middle or high dose either in a single injection or two separated by one month. The vaccine is based on the company’s Themaxyn platform, which was developed through a partnership with the Institut Pasteur.

Trial sites will be in either Germany or Austria, but the study “is aimed at the registration of our vaccine candidate on a world-wide basis,” CEO Erich Tauber said in a statement. The biotech plans further Phase II trials in the U.S. and Caribbean.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

"With outbreaks in many regions of the world, the Chikungunya virus remains a growing risk in endemic areas,” Tauber said in a statement. “A prophylactic vaccine against Chikungunya is highly desirable and we are happy to be able to offer this important vaccine candidate that is now undergoing a Phase 2 clinical trial."

Themis’ Phase II trial launch follows the company’s €10 million ($11.1 million) fundraise last year, a portion of which was to fund the trial. It also comes after the company in July expanded its Institut Pasteur partnership into Zika; it’s planning clinical trials within 12 months.

The NIAID is also working on a vaccine against chikungunya, which can cause fever and joint pain, among other symptoms. Additionally, just this week, Hawaii Biotech secured a NIAID small business research grant to work in the area. It’ll collaborate with the Baylor College of Medicine and the Sabin Vaccine Institute on a project utilizing the biotech’s vaccine platform.

- here’s the Themis release
- get more from Hawaii Biotech

Related Articles:
Themis rounds up new cash for Chikungunya jab's PhII
NIAID to bring Chikungunya vaccine into Phase II
Themis Biosciences nabs Institut Pasteur license for Zika vax; clinical trials planned

Suggested Articles

Traditional generics bigwigs Teva, Mylan, Sandoz, Amneal and Endo have lost out to a group of six competitors in terms of U.S. weekly prescriptions.

Roche’s Tecentriq scored some big wins lately, including a pair of first-in-class approvals. But in other cancers, it's decided to pull the plug.

Biosims haven't worked, experts say. Instead, it's time to for an independent body to set fair biologic prices after the drugs lose exclusivity.